Table 4.

Novel nonmarketed formulations for cancer therapy that have entered phase III clinical trials. SC: subcutaneous, IM: intramuscular, IV: intravenous, IL-10: interleukin 10.

Type of Therapy	Formulation Type	Mechanism of Action	Drug Substance	Trade Name	Administration Route	Indications	Clinical Trial Number	Current Status
Peptide-based therapy	Liposomes	Immunomodulation	Tecemotide	Stimuvax	SC	Non-small-cell lung cancer	NCT00409188	Completed
	Polymer conjugate	Arginine depletion	Pegargiminase	ADI-PEG 20	IM	Mesothelioma	NCT02709512	Recruiting
	Polymer conjugate	Hyaluronan degradation	Pegvorhyaluronidase alfa	PEGPH20	IV	Pancreatic cancer	NCT02715804	Terminated
	Polymer conjugate	Immunomodulation	Pegylated IL-10	Pegilodecakin	SC	Pancreatic cancer	NCT02923921	Completed
Chemotherapy	Liposomes	Topoisomerase-II inhibition, DNA intercalation	Doxorubicin	MM-302	IV	Breast cancer	NCT02213744	Terminated
	Liposomes	Topoisomerase-II inhibition, DNA intercalation	Doxorubicin	Thermodox	IV	Hepatocellular carcinoma	NCT00617981	Completed
							NCT02112656	Completed
	Liposomes	Microtubule inhibition	Paclitaxel	Endotag 1	IV	Breast cancer	NCT03002103	Recruiting
						Pancreatic cancer	NCT03126435	Recruiting
	Liposomes	DNA alkylation	Cisplatin	SPI-77	IV	Pancreatic cancer	NCT00416507	Completed
	Polymer conjugate	Topoisomerase I inhibition	Etirinotecan pegol	Onzeald	IV	Breast cancer	NCT01492101	Completed
							NCT02915744	Completed
	Micelles	DNA alkylation	Cisplatin	Nanoplatin	IV	Pancreatic cancer	NCT02043288	Completed
	Micelles	Microtubule inhibition	Paclitaxel	NK105	IV	Breast cancer	NCT01644890	Completed
	Polymeric nanoparticles	Topoisomerase-II inhibition, DNA intercalation	Doxorubicin	Livatag	IV	Hepatocellular carcinoma	NCT01655693	Completed